On August 10, 2026, the clinical trial registry recorded a status update for a study of setmelanotide. The trial, titled "A Trial of Setmelanotide in Acquired Hypothalamic Obesity," is registered under identifier NCT05774756. It is listed as a Phase 3 study. Its current status is active, not recruiting, meaning enrollment is closed but the trial continues.
This update reflects only the trial's administrative status as of the listed date. No results, efficacy data, or safety findings were included in this update. The trial record does not state when results might be posted or what outcomes are being measured in this update.
Setmelanotide is an approved compound. This particular trial update pertains specifically to its investigation in acquired hypothalamic obesity, a distinct condition from its currently approved uses. Readers should note that a trial being active and not recruiting indicates ongoing study activities such as follow-up or data collection, not the availability of new findings.
For more background on setmelanotide, including its approved indications and general information, see the compound overview.